YOLFTbeta
RenovoRx Inc

RenovoRx Inc

RNXT · NASDAQ · Healthcare / Biotechnology

1.04USD-0.12 (-10.34%)

Price History

Full chart

Market Stats

Previous Close1.16
Open1.18
Day Range1.04 – 1.20
52-Week Range0.701 – 2.59
Volume815.14K
Market Cap74.91M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.31
Dividend Yield0.00%
Beta1.12
50-Day Avg1.40
200-Day Avg1.05

About

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Shaun R. Bagai
  • Employees17
  • Headquarters2570 West El Camino Real, Mountain View, CA, United States, 94040, USA
  • Websitehttps://renovorx.com

Leadership

  • Dr. Ramtin Agah M.D.Founder, Executive Chairman & Chief Medical Officer · b. 1966
  • Mr. Shaun R. BagaiCEO, Secretary & Director · b. 1977
  • Mr. Ronald B. Kocak CPA, CGMAVP of Finance & Controller · b. 1958
  • Mr. Mark VollCFO & Principal Accounting Officer · b. 1955
  • Mr. Tom KellyVice President of Quality & Operations
  • Mr. Phil StoctonVice President of Sales & Market Development
  • Ms. Leesa GentryChief Clinical Officer · b. 1970

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue0000043.00K1.12M
Growth (%)------+2511.63%
Cost of Revenue--9.00K6.00K00327.00K
Gross Profit---9.00K-6.00K043.00K796.00K
Gross Margin-----100.00%70.88%
Operating Expense--5.66M9.94M11.40M11.01M13.31M
Operating Income-3.90M-3.20M-5.67M-9.95M-11.40M-10.97M-12.51M
Operating Margin------25511.63%-1113.98%
EBITDA-3.84M-3.21M-5.48M-9.94M-10.12M-8.81M-11.17M
EBITDA Margin------20497.67%-994.30%
Net Income-3.84M-3.80M-6.32M-9.77M-10.23M-8.81M-11.17M
Net Income Margin------20497.67%-994.48%
R&D3.00M2.39M3.04M4.30M5.67M6.03M6.27M
R&D as % of Total Revenue-----14011.63%558.24%
Interest Expense0590.00K904.00K57.00K108.00K384.00K-
Interest Expense % of Total Revenue-----893.02%-

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.27M1.91M16.29M7.26M1.47M8.12M8.10M
Total Liabilities805.00K16.57M938.00K1.10M4.47M3.64M2.67M
Total Equity1.47M-14.66M15.35M6.16M-3.00M4.48M5.42M
Cash2.10M1.79M15.19M4.39M1.17M7.15M7.02M
Total Debt12.39M2.79M---278.00K212.00K
Net Debt-2.10M995.00K-15.19M-4.39M-1.17M-6.88M-6.81M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.35M-3.53M-5.92M-8.81M-10.26M-9.13M-10.97M
Investing Cash Flow-1.00K-15.00K-15.00K-2.03M2.03M-12.00K-2.00K
Financing Cash Flow3.20M3.20M19.33M42.00K5.01M15.12M10.85M
Capital Expenditure15.00K15.00K15.00K0012.00K2.00K
Free Cash Flow-3.35M-3.53M-5.93M-8.81M-10.26M-9.14M-10.97M
FCF to OCF100.00%100.00%100.25%100.00%100.00%100.13%100.02%

Earnings

Report DateMar 31, 2020Jun 30, 2020Mar 31, 2021Jun 30, 2021Aug 27, 2021Nov 15, 2021Mar 30, 2022May 13, 2022Aug 12, 2022Nov 14, 2022Mar 2, 2023May 12, 2023Aug 16, 2023Nov 13, 2023Mar 19, 2024Apr 1, 2024Aug 13, 2024Nov 13, 2024Dec 31, 2024May 15, 2025Aug 14, 2025Nov 13, 2025Dec 31, 2025May 14, 2026Aug 12, 2026Nov 12, 2026
EPS Estimate0.000.000.000.00-0.58-0.21-0.16-0.21-0.28-0.29-0.26-0.25-0.29-0.28-0.30-0.30-0.11-0.12-0.13-0.08-0.08-0.08-0.08-0.08-0.08-0.05
EPS Actual-0.48-0.35-0.51-0.57-0.48-0.27-0.12-0.33-0.29-0.24-0.23-0.36-0.22-0.13-0.31-0.30-0.10-0.10-0.12-0.08-0.08-0.08-0.08-0.08-0.05-
Surprise----17.24%-28.57%25.00%-57.14%-3.57%17.24%11.54%-44.00%24.14%53.57%-3.33%0.00%9.09%16.67%4.00%0.00%0.00%0.00%0.00%0.00%37.50%-
Timing----Pre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap74.91M
Enterprise Value64.47M
Trailing P/E0.00
Forward P/E0.00
Price / Sales37.91
Price / Book8.19
EPS-0.31
Book Value0.199
Revenue (TTM)1.98M
Gross Profit (TTM)1.67M
EBITDA-13.03M
Profit Margin0.00%
Operating Margin-368.43%
Return on Equity-125.23%
Return on Assets-64.90%
Shares Outstanding45.13M
Shares Float39.17M
Beta1.12
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 4 analystsTarget 7.13
  • Strong Buy
    2
  • Buy
    2

Ownership Breakdown

Institutions
20.38%
Insiders
3.60%
Retail / Other
76.02%

Top Institutional Holders

  • AIGH Capital Management, LLC
    4.41M9.76%
  • Bleichroeder LP
    1.67M3.69%
  • Vanguard Capital Management, LLC
    1.45M3.21%
  • Geode Capital Management, LLC
    381.72K0.85%
  • Sontag Advisory LLC
    252.53K0.56%
  • Vanguard Fiduciary Trust Co
    157.90K0.35%
  • Citadel Advisors Llc
    133.60K0.30%
  • Northwestern Mutual Wealth Management Co
    99.46K0.22%
  • Chicago Partners Investment Group LLC
    92.36K0.20%
  • Caprock Group Inc
    63.94K0.14%
  • HRT FINANCIAL LLC
    43.12K0.10%
  • Northern Trust Corp
    42.16K0.09%
  • Kestra Advisory Services, LLC
    35.52K0.08%
  • XTX Topco Ltd
    30.51K0.07%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    1.18M2.62%
  • Fidelity Extended Market Index
    201.96K0.45%
  • Fidelity Total Market Index
    77.98K0.17%
  • Fidelity Series Total Market Index
    49.55K0.11%
  • Fidelity Nasdaq Composite Index
    37.16K0.08%
  • Vanguard Balanced Index Inv
    29.63K0.07%